Evidence map›Paper›PMID 41789413›Full record

ArticleFrontiers in nuclear medicine2026

Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with post-treatment glioma.

Dylan Henssen, Michael Rullmann, Andreas Schildan, Stephan Striepe, Matti Schürer, Cordula Scherlach, Katja Jähne, Ruth Stassart, Osama Sabri, Clemens Seidel and 1 more

Abstract read
In one paragraph

Article in Frontiers in nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dylan HenssenDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Michael RullmannDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Andreas SchildanDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Stephan StriepeDepartment of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
Matti SchürerDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Cordula ScherlachInstitute for Neuroradiology, University Hospital Leipzig, Leipzig, Germany.
Katja JähneDepartment of Neurosurgery, University Hospital Leipzig, Leipzig, Germany.
Ruth StassartInstitute of Neuropathology, University of Leipzig, Leipzig, Germany.
Osama SabriDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Clemens Seidel *Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
Swen Hesse *Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It remains unclear whether dynamic amino-acid (AA) positron-emission tomography (PET) has additional diagnostic value over static AA-PET to distinguish tumor progression (TP) from treatment-related abnormalities (TRA) in patients with post-treatment glioma. Methods: This was a retrospective study of patients with glioma with suspected TP who underwent dynamic AA-PET imaging. The final diagnoses were based on histopathology and/or clinical-radiological follow-up. The static PET parameters included the mean and maximum tumor-to-brain ratio (TBR Results: In total, 33 patients with adult diffuse glioma (17 females: mean age: 55.7 ± 12.2 years) were included [13 [S-methyl- Conclusion: This study suggests that dynamic and static AA-PET parameters have similar diagnostic capacities to distinguish TP from TRA. While static AA-PET parameters may suffice for clinical decision-making, this study did not formally assess the incremental value of using dynamic metrics in addition to static measures.

Indexed as

amino acid PETmolecular imagingneuro-oncologic emergencyPET-MRIpseudoprogressionradionecrosis

Identifiers

PMID41789413
PMCPMC12957138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.